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Background and Purpose: It is well known that there is a wide range of
different pathological stages related to Alzheimer’s disease (AD) among patients with
amnestic mild cognitive impairment (aMCI). Further refinement of the stages based on
neuropsychological and neuroimaging methods is important for earlier disease detection,
as well as for the development and evaluation of disease-modifying interventions.
Materials and Methods: In this cross-sectional study, 125 aMCI patients were
classified into declined progressively three stages of mild, moderate and severe, utilizing
the extreme groups approach (EGA) based on their memory function. Fifty-two patients,
in addition to 24 cognitively normal subjects, were included in further structural MRI
analyses. Characteristics of cognitive functions and brain structures across these newly
defined stages were explored through general linear models.
Results: Almost all the non-memory cognitive functions showed progressive decline
as memory function deteriorated. In addition, medial structures including the right
hippocampus, right lingual and left fusiform gyrus, presented with greater gray matter
(GM) atrophy during the later stages of aMCI (corrected p < 0.05). Correlations were
found between GM volume of the lingual gyrus and processing speed (r = 0.419,
p = 0.003) and between the fusiform gyrus and general cognitive function (r = 0.281,
p = 0.046). Moreover, both cognitive function and GM volume presented non-linear
trajectories over stages of aMCI.
Conclusion: Our study characterized the cognitive profiles along with the degree
of episodic memory impairment, and these three stages of aMCI showed non-linear
progressive decline in cognitive functions and GM volumes.
Keywords: amnestic mild cognitive impairment, cognition, medial temporal lobe, gray matter volume, voxel-based
morphometry
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INTRODUCTION
Amnestic mild cognitive impairment (aMCI) has been widely
viewed as the transitional preclinical stage between normal aging
and the onset of Alzheimer’s disease (AD). Substantial studies
have investigated aMCI from various perspectives, uncovering
how strikingly similar its clinical and pathological changes are to
those of AD (Mariani et al., 2007; Petersen, 2011; Mufson et al.,
2012). Furthermore, as the higher incidence of AD progression
(Mitchell and Shiri-Feshki, 2009; Petersen et al., 2014) and faster
cortical reduction in AD vulnerable regions (Thompson et al.,
2003; Chetelat et al., 2005; Jack et al., 2008; Desikan et al.,
2009; Mueller et al., 2010; Okonkwo et al., 2010) present in
aMCI cohorts, aMCI has become a focus for the early diagnosis
and secondary prevention of AD and indicates that there is
a crucial time window for emerging AD-modifying therapies.
Increasing evidence points to the fact that the current aMCI
inclusion criteria indeed cover a wide spectrum of different
pathological stages. While a subset of aMCI patients did not
show any detectable structural or functional abnormalities in
their brain, others manifested pathological changes comparable
with those of AD patients, although similar cognitive impairment
was detected. Because of this great variability, the depiction
of biomarker trajectories over various disease stages may be
imprecise, and thus, disease-modifying intervention would be
likely to be underpowered and even impeded by the underlying
variability. Therefore, the further refinement of the clinical
course of aMCI is of great importance to determine the effective
time window for more accurate early diagnosis, prognosis and
intervention evaluations.
Studies have begun to focus on the issue of aMCI staging.
A dichotomy of early and late MCI was put forward by
ADNI and several other groups (Aisen et al., 2010; Ye et al.,
2013, 2014; Zhuang et al., 2013; Jessen et al., 2014). With
this refinement, AD advancement corresponded better with the
severity of brain structural atrophy (Ye et al., 2014). Due to
the prominent impairment of episodic memory in aMCI and
AD patients (Albert et al., 2011; Gallagher and Koh, 2011;
Petersen, 2011) and the attempts of using episodic memory
to predict the conversion to AD in aMCI patients or normal
elders (Chapman et al., 2011; Didic et al., 2013; Gainotti et al.,
2014), the emerging dichotomy was mostly based on whether
a person scored 1.0 SD or 1.5 SD below the mean of standard
test norms on several episodic memory tests (Ye et al., 2013,
2014; Jessen et al., 2014). Although this dichotomy is sufficient
for characterizing monotonic change, it may be impossible to
capture some nonlinear trends for cognition or neuroimaging
biomarkers.
In this study, we attempted to further refine the staging
of aMCI patients based on their episodic memory function
and to explore the corresponding characteristics and
patterns in their cognitive profiles. We then addressed
brain structural alterations over these stages along with
declines in cognitive function. Finally, we studied the
relationship between cognitive function and brain gray
matter (GM) volume during the disease development. Our
findings provide further information for understanding the
aMCI stages and the disease’s progression, and contribute
to earlier disease detection and better disease-modifying
interventions.
METHODS
Study Cohort
As one of the leading groups, we conducted the Beijing Aging
Brain Rejuvenation Initiative (BABRI) investigation on the aging
and cognitive impairment of urban elderly people in Beijing,
China, and on neuroimaging biomarker identifications for MCI
and AD risks. The details of the BABRI project design and the
recruitment strategy are described elsewhere (Li et al., 2013).
So far, we have collected demographic, neuropsychological and
neuroimaging data from 1371 subjects, who (a) were 50–80 years
old, (b) had at least 6 years of education, (c) scored 24 or higher
on the Chinese version of the Mini-Mental State Examination
(MMSE) (Folstein et al., 1975), (d) had no history of neurological,
psychiatric, or systemic illness, and (e) had no history of using
psychoactive medications.
Among these 1371 subjects, we confirmed a total of 125
subjects who met the published criteria (Petersen, 2011) of
amnestic MCI, which included subjective memory complaints,
objective memory impairment (scoring more than 1.5 standard
deviations below the mean for age- and education-adjusted
norms on memory tests), relatively preserved general cognitive
function, and intact abilities in their daily life (scoring 0 on the
ADL scale).
These 125 aMCI patients were all included in the analyses of
cognitive status. For investigating the brain structural changes
and their associations with the cognition-based newly introduced
aMCI classification, 54 of these aMCI patients were enrolled in
the sub-imaging study for the acquisition of structural MRI data,
with two being excluded due to image quality. We also included
an additional 24 cognitively normal subjects from the BABRI
database with available MRI data who were matched for age,
gender, and education level.
All study procedures and ethical aspects of this research were
approved by the institutional review board of Beijing Normal
University Imaging Center for Brain Research. Written informed
consent was obtained from each participant.
Clinical Measures
Neuropsychological Assessment
All our teammembers who administered the neuropsychological
tests and questionnaire were well trained by professional
neuropsychologists.
In addition to the MMSE, which was used as a measure
of general cognitive function, all the subjects also underwent
a battery of neuropsychological tests to assess their cognitive
functions, including episodic memory, processing speed,
executive function and language ability. Details of these tests can
be found in our previous study (Li et al., 2013).
The raw scores of all tests were transformed to a scale
ranging from 0 to 10 based on all possible scores (if it had no
maximum, the highest observed score plus 1.5 SD of the norms
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was substituted), as per the following formula:
X′ = ([X − X_min]/[X_max− X_min]) ∗ 10,
if a theoretical maximum existed,
X′ = ([X − X_min]/[(X_max+ 1.5σ )− X_min]) ∗ 10,
if it did not.
For the tests scoring the subjects’ reaction times, the following
formula was utilized:
X′ = 10− ([X − X_min]/[(X_max+ 1.5σ )− X_min]) ∗ 10.
For a better overall assessment of the performance of certain
cognitive functions, the transformed scores within a cognitive
domain were averaged to obtain the function scores.
Classification of aMCI Patients
The memory tests used for the diagnosis of aMCI included long-
delay recall (trial 5) and total word recall (trial 1–5) of the R-
AVLT and delay recall of the ROCF. Memory impairment was
considered if the score was ≥1.5 SD below the mean when
compared with the age- and education-adjusted norms.
To classify the aMCI patients into different stages, we used the
extreme groups approach (EGA) (Feldt, 1961; Alf and Abrahams,
1975; Preacher et al., 2005) based on memory function scores.
Briefly, we computed episodic memory function scores by
averaging the transformed memory test scores, then ranked the
scores of aMCI patients in descending order and defined the
highest 27% as mild aMCI, the lowest 27% as severe aMCI, and
those in between as moderate aMCI.
Among the 125 consecutively recruited aMCI patients, there
were 33 mild aMCI patients, 57 moderate aMCI patients and 35
severe aMCI patients. The proportion of the three aMCI stages in
the sub-imaging study was similar (Chi-square test, p = 0.796),
with 12 mild, 24 moderate and 16 severe aMCI patients.
Data Acquisition of Sub Volumetric MRI
Study
Magnetic resonance imaging data acquisition was performed
using a Siemens Trio 3.0 Tesla scanner (Trio; Siemens, Erlangen,
Germany) in the Imaging Center for Brain Research at Beijing
Normal University. Foam padding and headphones were used
to reduce head motion and scanner noise. The patients were
instructed to keep still with their eyes closed. The T1-weighted
structural images were acquired using three-dimensional (3D)
magnetization prepared rapid gradient echo sequences: 176
sagittal slices, a repetition time of 1900 msec, an echo time of 3.44
msec, a slice thickness of 1 mm, a flip angle of 9◦, and a field of
view of 256× 256 mm.
Voxel-Based Morphometry Processing
Steps
The VBM8-toolbox (http://dbm.neuro.uni-jena.de/vbm) was
used to preprocess the structural images with the default
parameters, and the MNI East Asian brains template was used
for the Affine Regularization. The images were bias-corrected,
tissue classified, and normalized to MNI-space using linear
(12-parameter affine) and nonlinear transformations, within a
unified model (Ashburner and Friston, 2005) including the high-
dimensional DARTEL normalization. Gray and white matter
segments were modulated only by the nonlinear components to
preserve actual GM and WM values locally (modulated GM and
WM volumes).
Homogeneity of GM images was checked using the covariance
structure of each image with all other images, as implemented
in the check data quality function. Two extreme outliers
(one in each of the moderate and severe aMCI groups)
showing anatomical abnormalities or artifacts were identified
and excluded. The remaining n = 76 images were free of
any QC issues. The modulated GM images were smoothed
with a Gaussian kernel of 8 mm full-width-half-maximum
(FWHW).
Data Analysis
We first sought to characterize the non-memory cognitive
profiles of each stage of aMCI patients by using SPSS 22.0
(SPSS Inc. Chicago, IL, USA). ANOVA and chi-square tests were
performed to compare demographic variables among the groups.
ANCOVAs with age, gender and years of education as covariates
were performed to compare cognitive function scores, and for
multiple comparison correction, Bonferroni’s post-hoc analyses
were conducted. Further, general linear models were performed
to explore the change trajectories of cognitive function and
brain volume, and partial correlation analyses were conducted
to identify the relationship between brain volume and cognitive
functions, with age, gender and years of education as covariates in
above analyses. Thresholds for these analyses were set to p< 0.05.
To explore the brain structural differences, smoothed GM
images of mild, moderate and severe aMCI, with cognitively
normal subjects, were included in the random-effect group
analyses, as full-factorial analyses with age, gender and years
of education as covariates in SPM8 software (http://www.fil.ion.
ucl.ac.uk). Similar analyses within the three aMCI groups were
repeated to confirm these different regions. Post-hoc pairwise
analyses were run to determine which group(s) contributed to
the differences. All analyses were performed at the whole brain
level. The mean GM volume in those significant regions was then
extracted for further analyses. The threshold of significance for
all analyses was set at p< 0.05 by combining the individual voxel
p < 0.001 with a cluster size larger than 150 mm3, based on
Monte Carlo simulations (Ledberg et al., 1998).
RESULTS
Demographic Data and
Neuropsychological Profiles of the aMCI
Groups
There were no differences in the gender ratio or years of
education among the three groups. However, the severe aMCI
group was significantly older than the mild aMCI group. In the
examination of the neuropsychological test scores the moderate
and severe aMCI groups showed significantly lower scores on
the MMSE and SDMT (both p = 0.001) and longer reaction
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times on part B of the Stroop test (p = 0.038) than those in
the mild group. Trends for significantly lower scores or longer
reaction times were found in other tests. The general cognitive
function, processing speed and executive function of the aMCI
patients showed progressive declines from the mild group to the
severe group, whereas language function only presented a trend
of decline (see Table 1 and Figure 1). More specifically, besides
the linear decrease in general cognitive function and processing
speed (both p < 0.001), executive function was found to decline
in a sigmoidal pattern (p = 0.002), with language function being
exponential (p= 0.001).
To ensure that the aMCI subpopulation in the neuroimaging
sample was representative of the aMCI cohort, we compared their
demographic and neuropsychological profiles by independent
t-tests. As expected, there were no statistically significant
differences (data not shown). When we compared the aMCI
subpopulation with the CNs, aMCI patients showed significant
declines in all cognitive domains (see Supplementary Table 1,
Supplementary Figure 1).
VBM Data–Group Comparison for the
Imaging Sample
The full-factorial analyses revealed several areas where the local
GM volume showed significant differences among the newly
introduced stages of aMCI, including the typical vulnerable
regions of AD in the medial temporal lobe. Similar results were
found in the analyses among aMCI groups, combined or not with
the cognitively normal group (see Figure 2 and Supplementary
Figure 2). The right hippocampus and the lingual gyrus,
extending to parahippocampal gyrus and limbic structures,
showed prominent differences, with notable differences in the left
fusiform gyrus as well. Further pairwise analyses revealed that
the considerable structural atrophy of the severe aMCI group
TABLE 1 | Demographic and neuropsychological data of the aMCI population.
Mild aMCI Moderate aMCI Severe aMCI F-value (χ2) P-value
DEMOGRAPHIC
No. of Subjects 33 57 35
Age (years) 60.45 ± 7.10 62.77 ± 5.87 66.51 ± 8.09† 6.808 0.002
Years of Education (years) 10.42 ± 2.39 10.79 ± 2.35 11.34 ± 2.98 1.130 0.327
Gender (male/female) 16/17 23/34 15/20 0.566 0.754
GENERAL COGNITIVE FUNCTION
MMSE 27.27 ± 1.77 26.53 ± 1.74 25.20 ± 2.73†‡ 7.645 0.001
MMSE* 9.09 ± 0.59 8.84 ± 0.58 8.40 ± 0.91†‡ 7.645 0.001
EPISODIC MEMORY FUNCTION
RAVLT 20 min 2.91 ± 1.10 2.18 ± 1.12† 0.46 ± 0.66†‡ 45.947 <0.001
RAVLT (sum of five trials) 19.82 ± 5.35 18.00 ± 4.31 11.77 ± 3.53†‡ 28.939 <0.001
ROCF delayed 14.42 ± 7.01 7.65 ± 4.73† 4.97 ± 3.70†‡ 32.475 <0.001
Memory* 3.24 ± 0.33 2.31 ± 0.34† 1.24 ± 0.41†‡ 233.886 <0.001
LANGUAGE FUNCTION
CVFT 41.18 ± 7.53 37.37 ± 7.10 37.00 ± 7.36 2.816 0.064
BNT 22.45 ± 3.61 21.63 ± 3.75 20.83 ± 4.53 1.744 0.179
Language* 6.18 ± 0.88 5.82 ± 0.80 5.66 ± 0.99 2.939 0.057
ATTENTION/PROCESSING SPEED
SDMT 33.32 ± 8.86 29.34 ± 9.32 23.32 ± 7.39†‡ 7.493 0.001
TMT part A, sec 64.12 ± 24.85 65.53 ± 30.90 78.89 ± 28.45 1.234 0.295
Stroop part A, sec 29.79 ± 10.11 31.53 ± 8.15 33.21 ± 10.28 0.547 0.580
Stroop part B, sec 40.61 ± 10.11 45.37 ± 11.63 48.03 ± 14.43† 3.357 0.038
Process * 6.31 ± 0.68 6.04 ± 0.75 5.63 ± 0.85† 4.135 0.018
EXECUTIVE FUNCTION
TMT part B, sec 179.39 ± 52.03 216.42 ± 82.65 228.06 ± 64.55 2.226 0.112
TMT part B - A, sec 115.27 ± 38.45 150.89 ± 67.32† 149.17 ± 57.72 2.989 0.054
Stroop part C, sec 78.30 ± 18.64 91.09 ± 32.78 92.21 ± 29.22 1.767 0.175
Stroop part C - B, sec 37.70 ± 16.68 45.72 ± 28.03 44.18 ± 20.29 0.902 0.409
Execution* 7.74 ± 0.53 7.25 ± 0.86† 7.20 ± 0.68 3.631 0.030
Abbreviations: aMCI, amnestic mild cognitive impairment; MMSE, Mini-Mental State Examination; RAVLT, Rey’s Auditory Vocabulary List Test; ROCF, Rey-Osterrieth Complex Figure
test; CVFT, Category Verbal Fluency Test; BNT, Boston Naming Test; SDMT, Symbol Digit Modalities Test; TMT, Trail Making Test.
*Transformed or composited scores are presented. Data are presented as the mean ± SD.
One-way ANCOVA post-hoc Bonferroni tests are indicated by abbreviations:
†
p < 0.05, when compared to mild aMCI;
‡
p < 0.05, when compared to moderate aMCI. Age, gender
and years of education are covariates.
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contributed to all significances in comparison with the regional
volume (see Figure 3).
Among the aMCI groups, the mean GM volume alteration
in these ROIs were then fitted by general linear models. An
exponential model was found to best fit the volume changes in the
left fusiform gyrus (R2 = 0.36, standard β = −0.60, p < 0.001).
When the analyses were conducted on the other two ROIs from
the quadratic models that fit the data better (R2 = 0.39 for the
lingual gyrus, R2 = 0.32 for the hippocampus, both quadratic
coefficients <0, both p < 0.001), we found that the peaks of
these two curves fell around the mild stage (see Supplementary
Figure 3).
FIGURE 1 | Histogram of overall cognitive function among the aMCI
groups. Mean and standard errors of cognitive function scores, expressed as
transformed and/or composited scores, among three stages of aMCI patients
are presented.
Correlations between Non-memory
Cognitive Function and the GM Volume
Because the aMCI classification was based on memory function,
partial correlation analyses were conducted for the non-memory
cognitive functions. As shown in Figure 4, we found that
processing speed was significantly correlated with the GM
volume of the right lingual gyrus (r = 0.419, p = 0.003),
and significant correlations were also found between general
cognitive function and the GM volume of the left fusiform gyrus
(r = 0.281, p = 0.046), indicating that the decline of cognitive
functions might relate to the brain structural changes during
aMCI progression.
DISCUSSION
In the present study, we introduced a new way to categorize
aMCI patients as mild, moderate or severe based on their degree
of episodic memory dysfunction. Within a cohort of aMCI
patients, we found comprehensive functional decline along with
deterioration of memory function. Brain degenerative changes,
as expected, were more evident and extensive during the later
stages of aMCI. Furthermore, with this multi-staging aMCI
definition, certain non-linear trajectories of these cognitive and
GM changes could be characterized and were indeed uncovered
by our current study. Notably, we also found significant
correlations between cognitive function and brain structural
alterations.
Evidence from recent studies reflected a greater need for early
anti-AD interventions for earlier stage aMCI patients. This study
is our attempt to categorize aMCI patients into three stages
based on their episodic memory function in the hope that we
are more likely to observe the actual and progressive changes
en route to AD and that it would become feasible to depict
FIGURE 2 | Map of the significantly different regions in GM volume among three aMCI stages. Results were based on threshold at p < 0.05 by combining
the individual voxel p < 0.001 with a cluster size larger than 150 mm3, using Monte Carlo simulations (Ledberg et al., 1998).
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the non-linear trajectory if it does exist, rather than an artificial
linear one.
There are other ways of dividing aMCI patients into only two
stages, as presented in other studies. The Alzheimer’s Disease
Neuroimaging Initiative (ADNI) has recruited a group of subjects
with less severememory impairment than its originalMCI cohort
and referred them as in the earlier stage of MCI (E-MCI) (Aisen
et al., 2010), whereas other studies have defined the E-MCI
patients as those with memory scores between −1.5 and −1.0
SD below the age- and education-matched norms (Jessen et al.,
2014; Ye et al., 2014) or those who have not converted to AD
in a follow-up after 2 years (Zhuang et al., 2013). Although the
longitudinal method seems to be the best way to classify the aMCI
cohort, it may not be practical.
Episodic memory dysfunction has been considered as the
earliest and most common representation in aMCI due to AD,
and it has been more deteriorative during the progression toward
AD (Albert et al., 2011; Petersen, 2011; Braskie and Thompson,
2013). Recent studies have paid attention to the longitudinal
FIGURE 3 | Histogram of volumetric differences of significant regions
in VBM analyses among the three stages of aMCI. Mean and standard
errors of volumes in significant ROIs are presented. Significant differences are
only found in comparing the severe stage to the mild/moderate stage of aMCI.
cognitive changes in aMCI progression. Episodic memory was
reported to manifest significantly higher rate of decline in aMCI
patients who developed AD (Albert et al., 2007; Jack et al., 2008),
and it was among the cognitive functions that showed the earliest
and fastest decline during a follow-up of aMCI (Wilson et al.,
2011). The significant, consistent and characteristic memory
decrease in the disease progression is indeed a typical perspective
that can be more easily observed and retested.
Together with episodic memory dysfunction, the non-
memory cognitive function of aMCI patients showed a similar
progressive decline in our study, indicating that the progression
of aMCI was probably accompanied by systematic cognitive
degeneration. We further found that executive function and
language function declines were both relatively slower in the
later phase. These findings are consistent with several previous
longitudinal studies of aMCI (Albert et al., 2007; Wilson et al.,
2011) patients, which indicated that executive function and
working memory decline were accelerated earlier in aMCI
converters during follow-ups.
Changes in cortical GM volume were also identified based on
the three-stage definition in the present study. Regional reduction
was presented in the fusiform gyrus during the mild disease
stage, and more regions, such as the bilateral hippocampus and
right lingual gyrus extending to limbic area, were affected later.
Moreover, most of these brain regions exhibited nonlinear but
monotonic reductions in GM volume.
Though the current study is cross-sectional, our results
generally agreed with previous longitudinal studies concerning
the spatiotemporal pattern of cortical reduction in aMCI
progression. Cortical atrophy was first shown in the medial
temporal lobe, including the anterior hippocampus and fusiform
gyrus, and then in the rest of temporal lobe, the temporo-
parietal association cortices and the frontal lobe during the
conversion of aMCI (Whitwell et al., 2007; Spulber et al., 2012;
Yao et al., 2012). These results fit well with the Braak stage,
with the earliest neuropathological changes occurring in the
anterior medial temporal lobe and fusiform gyrus and then
spreading to the neocortex (Brettschneider et al., 2015). In
addition to the widespread cortical reduction, spatiotemporal
FIGURE 4 | Relationship between the GM volume measures and scores on non-memory cognitive domains.
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acceleration and/or deceleration of atrophy in the medial
temporal structures was also found during the aMCI progression,
including the hippocampus, parahippocampal gyrus, entorhinal
cortex, lingual gyrus, fusiform gyrus, posterior cingulate gyrus,
precuneus/cuneus and so on (Thompson et al., 2003; Chetelat
et al., 2005; McDonald et al., 2009; Sabuncu et al., 2011; Tosun
et al., 2011). The consistency between these longitudinal findings
and our cross-sectional results shows that our newly introduced
three-stage definition for aMCI is informative and meaningful.
The relationship between GM volume reduction and cognitive
decline was examined in this study. Except for episodic
memory, processing speed and general cognitive function were
correlated with brain structures. These findings are consistent
with studies concerning the cognitive changes in aMCI cohorts
(Mcdonald et al., 2012; Yao et al., 2012), as executive function
and processing speed are likely linked to posterior cortical
regions.
There were some limitations in the present study. First,
although size of our aMCI cohort was relatively large to examine
the patterns of cognitive changes, the association of cognition
and brain structure needs further confirmation due in part to the
smaller sample size in the MRI sub-study. Second, despite the
inclusion criteria and staging methods for our aMCI groups, it
was likely that some of our patients did not present due to AD
pathology. Finally, we noted that our nonlinear characterization
was mostly restrained to a quadratic model for depicting the
trajectories of GM volume alterations. Longitudinal studies
would have greater advantages in achieving a better fit with
cognitive and cortical data, thus accurately determining whether
patterns of regional longitudinal atrophy are different between
aMCI patients who have advanced or not.
CONCLUSIONS
Our study characterized the cognitive profiles and brain
structures along with the degree of episodic memory impairment,
as defined by the three-part staging introduced for aMCI
patients. These three aMCI stages showed progressive decline
in cognitive functions and reduced GM volumes in regions
such as the hippocampus, fusiform and lingual gyrus, which
had been previously reported in aMCI patients. More aMCI
neuropsychological and neuroimaging data are needed in future
longitudinal studies to identify the patterns of cortical atrophy
along with cognitive decline.
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